Chris Kim, Liminatus Pharma CEO

A fledg­ling biotech goes SPAC route to bankroll can­cer vac­cine, CAR-T and CD47

A rel­a­tive­ly un­known clin­i­cal-stage biotech — backed by a Ko­re­an light­ing com­pa­ny and fo­cused on a can­cer vac­cine out of a Thomas Jef­fer­son Uni­ver­si­ty lab …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.